Publications by authors named "W D Tap"
Article Synopsis
- Pexidartinib is a drug used for treating tenosynovial giant cell tumor (TGCT) in patients where surgery isn't an option, and this study looked at the effects of stopping and then restarting the medication.
- It was a phase 4 global study involving patients who had benefited from pexidartinib, allowing them to either continue treatment or stop with the option to restart later, monitoring their tumor progression and quality of life.
- Results showed that while about 54.5% of patients who stopped the drug experienced disease progression, none of those who continued treatment saw their condition worsen over a 24-month period.
Purpose: Survival of patients with metastatic sarcoma remains poor, and there is a pressing need for new therapies. Most sarcoma subtypes are not responsive to immune checkpoint inhibition alone. Lenvatinib, a multireceptor tyrosine kinase inhibitor targeting tumor vasculature, has an immunomodulatory activity that contributes to its antitumor effects.
View Article and Find Full Text PDFArticle Synopsis
- This phase II study (Alliance A091401) evaluates the effectiveness of nivolumab (N) alone and in combination with ipilimumab (N+I) on patients with different types of sarcomas, focusing on treatment responses and biomarkers.
- The study involved 66 patients with various sarcoma types, and while neither N nor N+I showed positive responses in gastrointestinal stromal tumors (GIST), N+I had a better response in dedifferentiated liposarcoma (DDLPS) and undifferentiated pleomorphic sarcoma (UPS).
- Results highlighted that traditional biomarkers did not predict immunotherapy response, but genomic instability markers correlated with better clinical outcomes, emphasizing the need for more research in
Article Synopsis
- Epithelioid hemangioendothelioma (EHE) is difficult to treat with traditional chemotherapy, prompting researchers to explore new therapies such as sirolimus and identify biomarkers for tumor aggressiveness.
- Scientists created a patient-derived xenograft (PDX) model from an advanced EHE patient to test sirolimus and to study serum levels of Growth/Differentiation Factor 15 (GDF-15) as a potential biomarker.
- The results indicated sirolimus was more effective than doxorubicin in reducing tumor growth and GDF-15 levels, establishing GDF-15 as a promising biomarker for EHE aggressiveness and potentially indicating the effectiveness of sirolimus in patients.